Rheumatoid Arthritis (RA) is considered the most common inflammatory form finally behind Arthritis, affecting more as compared to 2 million Americans. This is basically the chronic autoimmune inflammatory disease that causes systemic problems, meaning this affect internal organs, including lungs, heart, bone marrow, in spite of that eye. It is also a vital risk factor to add mass to cardiovascular complications such as stroke and cardiac arrest.
Added to these concerns is their major issue with Rheumatoid Arthritis which is that if not treated aggressively, it can result in irreversible joint damage, regular pain, and functional impairment.
While there is still no treatment of the disease yet, RA may be treatable and even put up to remission if diagnosed early and given urgency.
While many of the new medicines that have been developed in recent years are competent, there is still no consensus on which one to use introduction, which one to work second, when to alternate between the two drugs, when is some time to discontinue one drug and begin another, and so over.
Perhaps, in time we will be able to individualize Treatment programs. Progress as for what are called "biomarkers"- tissue evidence that can give us a unique profile of an given patient- will take us to the next level of Treatment.
A bright spot could possibly be the continued development of newer therapies based on a modes of action that will permit more choices, fewer negative effects, and more convenience.
Nonetheless, in fact it is clear right now constantly delaying proper Treatment results in functional decline that is hard, if not impossible, meant for reverse.
This loss of physical function might cause reduced productivity and heightened healthcare costs.
A number of studies have viewed various Treatment apparently and shown that a number of methotrexate, the disease-modifying anti-rheumatic prescribed medicines (DMARD) of choice utilizing biologic drug leads above a significantly greater chance of improvement and fewer likelihood of unemployability.
Another study has demonstrated that stretch of time of disease and involving functional impairment correlate as well as higher medical costs that typically greater disability.
And an additional understand by Maetzel and colleagues showed that RA costs also seem like higher than that as far as other common medical conditions like OsteoArthritis and hypertension (Maetzel TABS, et al. Ann Rheum Dis 2004; 63: 395-401).
The major hurdle today is getting patients with early RA to an rheumatologist early and to be able to rheumatologist initiate aggressive Treatment quickly. More about this in future articles..